Document Detail


Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy.
MedLine Citation:
PMID:  22280355     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to test the hypothesis that administration of epigallocatechin-3-gallate (EGCG), a polyphenol present in abundance in widely consumed tea, inhibits cell proliferation, invasion, and angiogenesis in breast cancer patients. EGCG in 400 mg capsules was orally administered three times daily to breast cancer patients undergoing treatment with radiotherapy. Parameters related to cell proliferation, invasion, and angiogenesis were analyzed while blood samples were collected at different time points to determine efficacy of the EGCG treatment. Compared to patients who received radiotherapy alone, those given radiotherapy plus EGCG for an extended time period (two to eight weeks) showed significantly lower serum levels of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and reduced activation of metalloproteinase-9 and metalloproteinase-2 (MMP9/MMP2). Addition of sera obtained from patients treated with combination of radiotherapy and EGCG feeding for 2-8 weeks to in vitro cultures of highly-metastatic human MDA-MB-231 breast cancer cells resulted in the following significant changes: (1) suppression of cell proliferation and invasion; (2) arrest of cell cycles at the G0/G1 phase; (3) reduction of activation of MMP9/MMP2, expressions of Bcl-2/Bax, c-Met receptor, NF-κB, and the phosphorylation of Akt. MDA-MB-231 cells exposed to 5-10 µM EGCG also showed significant augmentation of the apoptosis inducing effects of γ-radiation, concomitant with reduced NF-κB protein level and AKT phosphorylation. These results provide hitherto unreported evidence that EGCG potentiated efficacy of radiotherapy in breast cancer patients, and raise the possibility that this tea polyphenol has potential to be a therapeutic adjuvant against human metastatic breast cancer.
Authors:
G Zhang; Y Wang; Y Zhang; X Wan; J Li; K Liu; F Wang; K Liu; Q Liu; C Yang; P Yu; Y Huang; S Wang; P Jiang; Z Qu; J Luan; H Duan; L Zhang; A Hou; S Jin; T-C Hsieh; E Wu
Related Documents :
22534285 - Coexistence of benign phyllodes tumor and invasive ductal carcinoma in distinct breasts...
18034025 - Locked nailing for metastatic disease of the long bones.
6823725 - Renal carcinoma manifesting as breast mass.
22504175 - Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: an ...
22534285 - Coexistence of benign phyllodes tumor and invasive ductal carcinoma in distinct breasts...
11354745 - Evaluation of breast lesions by power doppler sonography.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current molecular medicine     Volume:  12     ISSN:  1875-5666     ISO Abbreviation:  Curr. Mol. Med.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-27     Completed Date:  2012-05-24     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  101093076     Medline TA:  Curr Mol Med     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  163-76     Citation Subset:  IM    
Affiliation:
Laboratory of Molecular Pharmacology, School of Pharmacy, Yantai University, Yantai, Shandong Province 264005, China. zhang_zhang6173@yahoo.com.cn
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Antineoplastic Agents, Phytogenic / administration & dosage,  pharmacology,  therapeutic use*
Apoptosis / drug effects
Breast Neoplasms / drug therapy*,  radiotherapy
Catechin / administration & dosage,  analogs & derivatives*,  pharmacology,  therapeutic use
Cell Cycle Checkpoints / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Chemotherapy, Adjuvant
Enzyme Activation / drug effects
Female
Gene Expression Regulation, Neoplastic / drug effects
Hepatocyte Growth Factor / blood
Humans
Matrix Metalloproteinase 2 / metabolism
Matrix Metalloproteinase 9 / metabolism
Middle Aged
NF-kappa B / metabolism
Neoplasm Invasiveness / prevention & control
Phosphorylation / drug effects
Proto-Oncogene Proteins c-akt / metabolism
Proto-Oncogene Proteins c-bcl-2 / metabolism
Proto-Oncogene Proteins c-met / metabolism
Tea / chemistry*
Vascular Endothelial Growth Factor A / blood
bcl-2-Associated X Protein / metabolism
Grant Support
ID/Acronym/Agency:
P20 GM103505-08/GM/NIGMS NIH HHS; P20 RR020151/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/NF-kappa B; 0/Proto-Oncogene Proteins c-bcl-2; 0/Tea; 0/Vascular Endothelial Growth Factor A; 0/bcl-2-Associated X Protein; 154-23-4/Catechin; 67256-21-7/Hepatocyte Growth Factor; BQM438CTEL/epigallocatechin gallate; EC 2.7.10.1/Proto-Oncogene Proteins c-met; EC 2.7.11.1/Proto-Oncogene Proteins c-akt; EC 3.4.24.24/Matrix Metalloproteinase 2; EC 3.4.24.35/Matrix Metalloproteinase 9
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hrd1 facilitates tau degradation and promotes neuron survival.
Next Document:  ?A- and ?B-Crystallins Interact with Caspase-3 and Bax to Guard Mouse Lens Development.